Jacqueline McBride

机构：VIR Biotechnology (United States) · ORCID：0000-0002-0247-6569

发表论文 112 篇 · 总被引 6836 次 · h-index 32

代表论文

• First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers (2023 · Clinical and Translational Science · 被引 62)
• Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 25)
• Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy (2024 · Journal of Crohn s and Colitis · 被引 15)
• Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19 (2023 · iScience · 被引 14)
• A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis (2024 · Clinical Gastroenterology and Hepatology · 被引 13)
• A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling (2023 · iScience · 被引 12)